Kevin Michael Lundquist
Chief Financial Officer · Outlook Therapeutics, Inc.
Individual
- 2026
- Sep 2, 2026
- 1
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Kevin Michael Lundquist files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ghiath M. Sukhtian - $7.50M in OTLK purchases and sales in the last 12 months
- Kurt J. Hilzinger - $177K in OTLK purchases and sales in the last 12 months
- Faisal Ghiath Sukhtian - $150K in OTLK purchases and sales in the last 12 months
- Yezan Munther Haddadin - $39K in OTLK purchases and sales in the last 12 months
- Randy H. Thurman - $2K in OTLK purchases and sales in the last 12 months
- Robert Charles Jahr - OTLK
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Kevin Michael Lundquist?
Kevin Michael Lundquist is a corporate insider, tracked as Chief Financial Officer of Outlook Therapeutics, Inc. (OTLK). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Kevin Michael Lundquist submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.